Table 7 Multivariate analysis with baseline prognostic factors

From: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702

Variables

P -value

Hazard ratio

95% CI

Treatment arm (CE vs. SPE)

0.99

0.99

0.75–1.33

Alkaline phosphatase level (normal vs abnormal)

0.97

0.99

0.68–1.46

Lactate dehydrogenase level

<0.001

1.69

1.23–2.26

(⩾ × 1.5 vs < × 1.5)

   

Leucocyte count

   

(⩾10 000/mm3 vs <10 000/mm3)

0.06

1.82

0.99–3.36

Age (⩾75 years vs <75 years)

0.77

1.05

0.78–1.41

PS (2–3 vs 0–1)

0.41

1.15

0.82–1.61

Sex (female vs male)

0.13

0.70

0.45–1.11

  1. CE=carboplatin plus etoposide; SPE=split doses of cisplatin plus etoposide; PS=performance status; CI=confidence interval.
Back to article page